Exchange: NYSE
Industry: Pharmaceuticals & Biotechnology
Last Trade: 4:00 PM ET 4/5/2013
Last 10 Quotes:
What's This?
| Most Recent Quarter ($) | Same Quarter Last Year ($) | % Change | |
| EPS, Pro Forma | 0.64 | 0.55 | 15.62 |
| EPS, GAAP | 0.55 | 0.50 | 0.50 |
| Consensus Estimate | 0.43 | 0.55 | -21.82 |
| Trailing 12 Months | Year-Earlier Period | % Change | |
| EPS, Pro Forma | 2.12 | 2.26 | -6.54 |
| EPS, GAAP | 1.16 | 2.16 | -46.16 |
| Consensus Estimate | 1.96 | 2.30 | -14.78 |
| BMY | Industry Average | |
| P/E (TTM) | 35.01 | NA |
| P/E (Forward) | 22.07 | NA |
| PEG Ratio | 2.55 | 2.20 |
| Price/Sales | 3.85 | 18.91 |
| Beta | 0.60 | 0.70 |
| 8:42 AM | 4/5/2013 | Vertex Signs Deal With Bristol-Myers for Hepatitis C Treatment Studies |
| 3:04 PM | 3/25/2013 | CEO Pay Declines at Lilly, Rises at Bristol-Myers |
| 4/4/2013 | The Morning Ledger: Pharma Firms Embrace Pay Clawbacks (WSJ.com) |
| 4/3/2013 | Drug Firms Expand Powers to Recoup Pay (WSJ.com) |
| 3/27/2013 | Merrill Lynch Picks Diabetes Drug Makers as Real Winners (MRK, BMY, LLY, NOV, MNKD, BAC) (24/7 Wall St) |
| 3/14/2013 | FDA Opens Safety Review of Diabetes Drugs (WSJ.com) |
| 3/14/2013 | Argus Changes Model Equity Income Portfolio Picks (RIG, AMAT, BMY, COP) (24/7 Wall St) |
| 3/13/2013 | A Dose of Defense in a Feel-Good Market (Barrons.com) |
| 3/10/2013 | Sanofi: U.S. Probes Disclosures About Plavix (WSJ.com) |
| 3/4/2013 | Deals of the Day: Cheap Oil Could Help Out Exxon (WSJ.com) |
